Aromatase Inhibitors

Subscribe to Selected New Research on Aromatase Inhibitors

983 relevant articles (116 outcomes, 163 trials/studies) found for this Bio-Agent

Description: Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.

Also Known As:

Inhibitors, Aromatase

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses

Pharmacologic Actions: 50

Molecular Mechanisms of Pharmacological Action: 5

Enzyme Inhibitors: 590

Aromatase Inhibitors: 983

Experts

1.	Dowsett, Mitch: 7 articles (06/2008 - 12/2002)
2.	Altundag, Kadri: 6 articles (05/2008 - 10/2004)
3.	Cuzick, Jack: 6 articles (04/2008 - 01/2003)
4.	Carlini, Paolo: 6 articles (01/2008 - 10/2005)
5.	Bria, Emilio: 6 articles (01/2008 - 10/2005)
6.	Giannarelli, Diana: 6 articles (01/2008 - 10/2005)
7.	Cognetti, Francesco: 6 articles (01/2008 - 10/2005)
8.	Pritchard, Kathleen I: 5 articles (04/2008 - 08/2002)
9.	Terzoli, Edmondo: 5 articles (01/2008 - 10/2005)
10.	Goss, Paul E: 5 articles (11/2006 - 01/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 02/01/2008 - "Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease." 07/01/1999 - "The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials" 04/01/1993 - "Aromatase inhibitors are known to be effective in the treatment of advanced postmenopausal breast cancer" 01/01/1998 - "The histoculture technique we used here is therefore expected to be useful in predicting the efficacy of aromatase inhibitors for individual patients with breast cancer." 05/01/1980 - "These results demonstrate that these aromatase inhibitors may be useful for the treatment of breast cancer." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 03/01/2006 - "In randomized clinical trials, each of the third-generation aromatase inhibitors (AIs) has demonstrated efficacy in the adjuvant treatment of postmenopausal women with receptor' -positive tumors" 06/01/2001 - "Recent clinical trials have demonstrated the efficacy and tolerability of the new generation of aromatase inhibitors as second-line and first-line therapy in postmenopausal women with breast cancers who were eligible for endocrine treatment" 05/01/2008 - "However, the effects of endocrine therapy with aromatase inhibitors on in vivo expression of this signaling cascade, and its relation to tumor response and patient outcome, is unknown" 12/01/2007 - "Application of aromatase inhibitors in endocrine responsive breast cancers." 08/01/2007 - "Aromatase inhibitors in gynecologic cancers." Get all the results and reference details, order at left...
3.	Endometriosis (Adenomyosis) 08/01/2004 - "Recent studies have provided evidence that aromatase inhibitors may be effective in the short term for induction of ovulation and in the long-term for treatment of endometriosis" 09/01/2003 - "The aromatase inhibitors may be also useful for the treatment of endometriosis and for ovulation induction as evidenced by preliminary data" 12/01/2003 - "Few studies report efficacy of aromatase inhibitors in human endometriosis" 01/01/2006 - "These basic findings led to recent phase-II studies employing aromatase inhibitors in the treatment of endometriosis" 05/01/2005 - "Successful treatment of endometriosis and uterine leiomyomata using aromatase inhibitors by recent pilot trials underscores the clinical significance of these molecular studies." Get all the results and reference details, order at left...
4.	Carcinoma (Carcinomatosis) 03/01/2006 - "The review summarizes the outcomes of several landmark trials involving aromatase inhibitors that helped formulate current therapeutic approaches recommended by the American Society of Clinical Oncology for breast carcinoma treatment." 10/01/2005 - "New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials." 07/01/2007 - "Aromatase inhibitors in post-menopausal metastatic breast carcinoma." 10/01/2004 - "The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M" 06/01/2004 - "Aromatase inhibitors in the adjuvant therapy of breast carcinomas]" Get all the results and reference details, order at left...
5.	Noninfiltrating Intraductal Carcinoma (DCIS) 08/01/2007 - "The few clinical data that are available therefore suggest the aromatase inhibitors are likely to be effective in DCIS" 08/01/2007 - "This study has shown significant effects of aromatase inhibitors on DCIS indicating that these agents are therapeutically active in this condition." 08/01/2007 - "Within the DCIS both aromatase inhibitors significantly reduced PgR expression and both drugs also produced a significant fall in proliferation" 08/01/2007 - "DCIS and aromatase inhibitors." 06/01/2004 - "This review focuses on data on aromatase inhibitors in the adjuvant setting and looks to the future potential of these drugs in both ductal carcinoma in situ and chemoprevention." Get all the results and reference details, order at left...
91 Diseases and 983 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Estrogens (Estrogen)
3.	Hormones
4.	anastrozole (Arimidex)
5.	letrozole (Femara)
6.	Estrogen Receptor Modulators (Antiestrogen)
7.	exemestane (Aromasin)
8.	Gonadotropin-Releasing Hormone (GnRH)
9.	Aromatase (CYP19)
10.	fulvestrant (Faslodex)
141 Drugs and Important Bio-Agents and 714 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Neoadjuvant Therapy
3.	Chemoprevention
4.	Ovariectomy (Oophorectomy)
5.	Adjuvant Chemotherapy
18 Therapies and Procedures and 61 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>